Thyrocare Technologies Ltd
BSE:539871
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
64.8B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
99.4B USD |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
77.6B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
65.2B EUR |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
28.8B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
24B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23.4B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.8B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.8B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
13.2B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.2B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Thyrocare Technologies Ltd is 16.7%, which is above its 3-year median of 13.1%.
Over the last 3 years, Thyrocare Technologies Ltd’s Net Margin has increased from 15.6% to 16.7%. During this period, it reached a low of 11.2% on Jun 30, 2023 and a high of 16.7% on Sep 30, 2025.
